

### FINANCIAL STATEMENTS WITH INDEPENDENT AUDITORS' REPORT

YEARS ENDED DECEMBER 31, 2024 AND 2023

### Years Ended December 31, 2024 and 2023

### CONTENTS

	<u>Page</u>
Independent Auditors' Report	1 - 2
Financial Statements:	
Balance Sheets	3
Statements of Activities	4
Statements of Cash Flows	5
Statements of Functional Expenses	6 - 7
Notes to Financial Statements	8 - 15



Park 80 West, Plaza Two 250 Pehle Ave., Suite 702 Saddle Brook, NJ 07663-5837

Tel: (201) 403-9750 Fax: (201) 403-9755 www.dorfman.com

### INDEPENDENT AUDITORS' REPORT

To The Board of Directors
The Barth Syndrome Foundation, Inc.
Larchmont, New York

### **Opinion**

We have audited the accompanying financial statements of The Barth Syndrome Foundation, Inc. (a nonprofit organization), which comprise the balance sheets as of December 31, 2024 and 2023, and the related statements of activities, cash flows, and functional expenses for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Barth Syndrome Foundation, Inc. as of December 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of The Barth Syndrome Foundation, Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about The Barth Syndrome Foundation, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

### Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of The Barth Syndrome Foundation, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about The Barth Syndrome Foundation, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Saddle Brook, New Jersey

Dorfman alrama muis, LLC

April 15, 2025

### BALANCE SHEETS

### **ASSETS**

		Decei	mber 3	31,
		2024		2023
Cash Investments Contributions receivable Prepaid expenses	\$	720,374 4,885,260 100 34,906	\$	460,296 4,982,899 48,135
Total assets	\$	5,640,640	<u>\$</u>	5,491,330
<u>LIABILITIES AND NET ASSETS</u>				
Liabilities: Accounts payable and accrued expenses Deferred revenue Grants payable	\$	163,444 256,910	\$	94,143 27,183 84,650
Total liabilities		420,354		205,976
Net assets: Without donor restrictions With donor restrictions  Total net assets		1,121,367 4,098,919 5,220,286		1,322,181 3,963,173 5,285,354
Total liabilities and net assets	<u> </u>	5,640,640	\$	5,491,330

### STATEMENTS OF ACTIVITIES

Contributions of cash and other financial assets

Operating activities: Support and revenue:

Affiliates' donation for research grants Contributions of nonfinancial assets

Interest and dividend income

Grant income Other revenue Total support and revenue

Net assets released from restrictions

Total support and revenue

Communication and awareness

Program services:

Expenses:

BSF Regional Meetings

Family services

Advocacy and awareness Barth registry and repository Research grants Science and medicine

Management and general

Fundraising

Supporting services:

Total program services

Total supporting services

Total expenses

1, 2023	Total	\$ 1,106,608 76,788	95,875 95,000	131,350	1,505,621		1,505,621	134,459	128,968	231,852	12,376	333,038 330,860	1,188,382	208,812 170,398	379,210	1,567,592	(61,971)	333,995	333,995	272,024 5,013,330	\$ 5,285,354
Year ended December 31, 2023 onor With donor	restrictions	\$ 155,089 76,788			231,877	(283,298)	(51,421)										(51,421)			(51,421) 4,014,594	\$ 3,963,173
Year e Without donor	restrictions	\$ 951,519	95,000	131,350	1,273,744	283,298	1,557,042	134,459	128,968	231,852	12,376	333,038 330,860	1,188,382	208,812 170,398	379,210	1,567,592	(10,550)	333,995	333,995	323,445 998,736	\$ 1,322,181
	Total	\$ 1,376,242 190,000	44,937 108,500 9,362	141,114	1,870,155		1,870,155	130,319	132,306	273,870	43,118	322,146 496,586	1,776,234	183,908 178,686	362,594	2,138,828	(268,673)	203,605	203,605	(65,068) 5,285,354	\$ 5,220,286
Year ended December 31, 2024 Ionor With donor	restrictions	\$ 124,108 190,000	100,000		414,108	(278,362)	135,746										135,746			135,746 3,963,173	\$ 4,098,919
Year en Without donor	restrictions	\$ 1,252,134	44,950 8,500 9,362	141,114	1,456,047	278,362	1,734,409	130,319	132,306	273,870	43,118	322,146 496,586	1,776,234	183,908 178,686	362,594	2,138,828	(404,419)	203,605	203,605	(200,814)	\$ 1,121,367

See notes to financial statements.

Realized and unrealized gains on investments, net

Nonoperating activities:

Total nonoperating activities

Change in net assets Net assets, beginning of year

Net assets, end of year

Change in net assets from operations

### STATEMENTS OF CASH FLOWS

	Year ended I	Decen	nber 31,
	2024		2023
Cash flows from operating activities: Change in net assets	\$ (65,068)	\$	272,024
Adjustments to reconcile change in net assets to net cash provided (used) by operating activities:			
Contribution of stock	(7,602)		(27,492)
Realized and unrealized gains on investments, net Changes in operating assets and liabilities: (Increase) decrease in:	(203,605)		(333,995)
Contributions receivable	(100)		103,000
Prepaid expenses	13,229		(5,680)
Increase (decrease) in:			
Accounts payable and accrued expenses	69,301		5,705
Deferred revenue	(27,183)		
Grants payable	 172,260		(158,399)
Net cash used by operating activities	 (48,768)		(144,837)
Cash flows from investing activities:			
Purchases of investments	(666,556)		(140,639)
Proceeds from sale of investments	 975,402		59,259
Net cash provided (used) by investing activities	 308,846		(81,380)
Net change in cash	260,078		(226,217)
Cash, beginning of year	 460,296		686,513
Cash, end of year	\$ 720,374	\$	460,296

THE BARTH SYNDROME FOUNDATION, INC. STATEMENTS OF FUNCTIONAL EXPENSES

Years Ended December 31, 2024 and 2023

								Program	Program services							
	Commur	Communication and					Advocacy and	cy and	Barth registry	gistry						
	awa	awareness	BSF Region	BSF Regional Meetings	Family services	services	awareness	ness	and repository	ository	Researc	Research grants	Science and medicine	id medicine	Total	<u>10</u>
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Salaries Payroll taxes and benefits	\$ 53,189 6,543	\$ 62,965	69	<b>↔</b>	\$ 78,006	\$ 77,513	\$ 115,579	\$ 103,263	\$ 8,555	↔	₩	€	\$ 310,568	\$ 214,796	\$ 565,897	\$ 458,537
Total salaries and									8				30,120	35,730	010,01	800'8/
related expenses	59,732	72,843			94,647	94,790	134,192	122,767	9,451				346,688	247,526	644,710	537,926
Research grant expense											322,746	333,038			322,746	333,038
Research grants funded by affiliates													110,000		110,000	
Professional fees	52,250	(1)	62,000	6,000	26,196		50,000	10,000	32,794	11,500			16,803	63,672	240,043	130.317
Office and other expenses	606'9	6,079	32,250	585	9,360	6,336	3,370	396	128	131			9,070	6,033	61,087	19,560
III-KIII'U proressioriai services			107					95,875								95,875
Dripting and publications	1 400		192,197	10,244	1,194		84,218	2,814					6,667	7,196	287,276	42,542
Prior and foor	1,428	16,392	13,554		9	2,560									20,982	18,952
Dues and rees Insurance					403	700			745	745			3,720	6,433	4,868	7,878
Telephone					506	695									508	808
Training and education						666										0 66 66 66
Public relations			;										638		638	
Audio Visual	4,000		63,151			009	2,090								69,241	009
Even cost			14,13/												14,137	
Total expenses	\$ 130,319	\$ 134,459	\$ 377,289	\$ 16,829	\$ 132,306	\$ 128,968	\$ 273,870	\$ 231,852	\$ 43,118	\$ 12,376	\$ 322,746	\$ 333,038	\$ 496,586	\$ 330,860	\$ 1,776,234	\$ 1,188,382

See notes to financial statements.

THE BARTH SYNDROME FOUNDATION, INC.

# STATEMENTS OF FUNCTIONAL EXPENSES

Years Ended December 31, 2024 and 2023

	Managemen	Management and general	Supportir	Supporting services Fundraising	) <u> </u>	Total	Total pro	Total program and supporting services
	2024	2023	2024	2023	2024	2023	2024	2023
Salaries Payroll taxes and benefits	\$ 43,690	\$ 48,390 7,807	\$ 128,008	\$ 113,671 18,881	\$ 171,698 24,445	\$ 162,061 26,688	\$ 737,595 103,258	\$ 620,598 106,077
Total salaries and related expenses	49,444	56,197	146,699	132,552	196,143	188,749	840,853	726,675
Research grant expense Grant expenses							322,746	333,038
Professional fees	79,452	92,138	5,200	5,400	84,652	97,538	324,695	227.855
Office and other expenses	39,466	50,142	22,484	21,100	61,950	71,242	123,037	90,802
In-kind protessional services								95,875
Iravel		84		1,699		1,783	287,276	44,325
Printing and publications		289	4,065	7,269	4,065	7,558	25,047	26,510
Dues and fees	6,868	3,840		1,200	6,868	5,040	11,736	12,918
Insurance	7,724	4,379			7,724	4,379	7,724	4,979
Telephone	954	1,029			954	1,029	1,460	1,724
Training and education				646		646		646
Public relations		714	38	212	38	926	929	926
Audio visual Event cost			200	320	200	320	69,441 14,137	1,319
Total expenses	\$ 183,908	\$ 208,812	\$ 178,686	\$ 170,398	\$ 362,594	\$ 379,210	\$ 2,138,828	\$ 1,567,592

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 1. <u>Nature of the Organization</u>

The Barth Syndrome Foundation, Inc. (the Organization) is a not-for-profit organization incorporated under the laws of the State of Delaware on September 8, 2000 to be operated for the following purposes: a) to support and educate families with children suffering from Barth syndrome; b) to fund and facilitate research addressing the causes, diagnosis, treatments, and cure of Barth syndrome; and c) to raise physician awareness regarding Barth syndrome. The Organization has entered into licensing agreements with several not-for-profit entities dedicated to Barth syndrome in other countries. The agreements allow for each of these entities (the affiliates) to use The Barth Syndrome Foundation, Inc. brand in their various communications and to share in the Organization's programs including the biennial International Barth Syndrome Scientific, Medical and Family Conference, newsletters, websites and research and development initiatives, among others.

### 2. Summary of significant accounting policies

### Basis of presentation

The financial statements of the Organization have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (U.S. GAAP), which require the Organization to report information regarding its financial position and activities according to the following net asset classifications:

<u>Net assets without donor restrictions</u> - Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of the Organization's management and the board of directors.

<u>Net assets with donor restrictions</u> - Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Organization or by the passage of time. Other donor restrictions are perpetual in nature, where by the donor has stipulated the funds be maintained in perpetuity.

### Measure of operations

The statement of activities reports all changes in net assets, including changes in net assets from operating and nonoperating activities. Operating activities consist of those items attributable to the Organization's ongoing services and interest and dividend income earned on investments. Nonoperating activities are limited to resources that generate return from investments and other activities considered to be of a more unusual or nonrecurring nature.

### Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

### Cash

Cash consist of demand deposit accounts. Money market funds, held as a portion of the Organization's investment portfolio, are classified as investments and are not considered to be cash equivalents for purposes of the statement of cash flows.

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 2. Summary of significant accounting policies (continued)

### Investments

Investments are recorded at cost, or if donated, at fair value on the date of donation. Thereafter, investments are reported at their fair values on the balance sheet. Unrealized gains and losses are included in the changes in net assets without donor restriction for the gains and losses that are unrestricted, and in the changes in net assets with donor restriction for the gains and losses that are restricted for the support of certain programs. Investment fees are netted against the investment income.

### Fair value measurement

U.S. GAAP establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy are as follows:

Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Organization has the ability to access at the measurement date;

Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs that are not considered to be active;

Level 3 - Inputs that are unobservable.

Inputs are used in applying the various valuation techniques and broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad criteria data, liquidity statistics, and other factors. An investment's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes "observable" requires significant judgment by the Organization. The Organization considers observable data to be that market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, provided by multiple, independent sources that are actively involved in the relevant market. The categorization of an investment within the hierarchy is based upon the pricing transparency of the investment and does not necessarily correspond to the Organization's perceived risk of that investment.

The following is a description of the valuation methodologies used for assets measured at fair value.

**Money market funds, fixed-income securities and equities** - Valued at the closing price reported on the active market on which the individual securities are traded.

**Convertible Promissory Note** - There are no observable inputs and certain of the underlying investments are not publicly traded and there is no secondary market for such funds. These funds are valued by the managers of the underlying funds at the NAV of shares held by the Organization at year end or other pricing methodologies.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 2. Summary of significant accounting policies (continued)

### Contributions receivable

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. The discounts on those amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Conditional promises to give are not included as support until the conditions are met.

### Allowance for doubtful accounts

The Organization uses the allowance method to account for uncollectible contributions receivable. The allowance for doubtful accounts is based on prior years' experience and management's analysis of possible bad debt. As of December 31, 2024, and 2023, the Organization determined that an allowance was not necessary.

### Revenue recognition

The Organization recognizes contributions when cash, investments or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Contributions received are recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor-imposed restrictions. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Conditional promises to give – that is, those with a measurable performance or other barrier and a right of return – are not recognized until the conditions on which they depend have been met.

The Organization receives grants from its affiliate organizations to fund a portion of the grants the Organization pays to the grantees. This revenue is recognized when the grants are committed to being paid by the affiliate organizations.

The Organization recognizes revenue from conferences when the event takes place. Conferences are generally held every other year. Amounts received prior to the commencement of the conference, including deposits, are deferred to the applicable period.

### Contribution of nonfinancial assets

The Organization receives donated services from specialized providers and other volunteers that create or enhance non-financial assets and allow the Organization to fulfill its mission. Donated specialized services have been recognized on the accompanying financial statements at their fair value at the date of donation and are reported as support without donor restrictions unless explicit donor stipulations specify how donated assets must be used. These donated services require professional skills, and would typically need to be purchased if not provided by donation. Such specialized donated services amounted to \$44,937 and \$95,875 as of December 31, 2024 and 2023, respectively. (See Note 9).

### Functional allocation of expenses

The costs of providing various programs and support services have been summarized on a functional basis in the statement of activities and in the statement of functional expenses. Accordingly, natural expenses attributable to more than one functional expense category are allocated using a variety of cost allocation techniques such as time and effort.

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 2. <u>Summary of significant accounting policies (continued)</u>

### Income taxes

The Organization is a tax-exempt organization as defined by Section 501(c)(3) of the Internal Revenue Code, though it is subject to tax on income unrelated to its exempt purpose, unless that income is otherwise excluded by the Code. The Organization is also exempt from New York State income taxes. The Organization has procedures in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The Organization has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements.

### Reclassifications

Certain amounts in the 2023 financial statements have been reclassified to conform to the 2024 presentation.

### 3. Risks and uncertainties

### Concentrations of credit risk

Financial instruments that potentially subject the Organization to concentrations of credit risk consist principally of cash, investments and contributions receivable. The Organization maintains its cash in bank deposit accounts, the balances of which, at times, may exceed federally insured limits. Investments are exposed to various risks. Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in the value of investments will occur in the near term and that such changes could materially affect the amount reported on the financial statements. Concentrations of credit risk with respect to contributions receivable are limited due to the short payment terms the Organization has with its creditors. The Organization has not experienced, nor does it anticipate, any losses with respect to such accounts.

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 4. Availability and liquidity

The following represents the Organization's financial assets at December 31, 2024:

Financial assets at year-end:

Cash Investments Contributions receivable	\$	720,374 4,885,260 100
Total financial assets		5,605,734
Less amounts not available to be used within one year:		
Net assets with donor restrictions Less net assets with purpose restrictions to be met		4,098,919
in less than a year		(338,179)
Financial assets available to meet cash needs for	***************************************	3,760,740
general expenditures within one year	\$	1,844,994

The Organization's goal is generally to maintain financial assets to meet 90 days of operating expenses, net of in-kind (approximately \$440,000). As part of its liquidity plan, excess cash is invested in short-term investments, including money market accounts. In addition to their available financial assets, a significant portion of the Organization's annual expenditures will be funded by current year operating revenues including grants and contributions.

### 5. <u>Investments</u>

Investment securities are stated at fair value and summarized as follows at December 31:

	 2024	 2023
Cash and money market Equities Fixed income Convertible Promissory Note	\$ 483,147 1,748,677 2,628,436 25,000	\$ 810,405 1,660,527 2,486,967 25,000
	\$ 4,885,260	\$ 4,982,899

The following schedule summarizes the investment return and its classification in the statement of activities for the years ended December 31:

Investments:	 2024	 2023
Interest and dividend income Realized and unrealized gains, net	\$ 141,114 203,605	\$ 131,350 333,995
	\$ 344,719	\$ 465,345

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 6. Fair value measurement

The classifications of the Organization's investment securities at fair value are as follows at December 31, 2024:

	Level 1	Level 2	Level 3	Total
Money market funds (at cost)	\$	\$	\$	\$ 483,147
Equities	1,748,677			1,748,677
Fixed income		2,628,436		2,628,436
Convertible promissory note			25,000	25,000
	\$ 1,748,677	\$ 2,628,436	\$ 25,000	\$ 4,885,260

The classifications of the Organization's investment securities at fair value are as follows at December 31, 2023:

	Level 1	Level 2	Level 3	Total
Money market funds (at cost) Equities	\$ 1,660,527	\$	\$	\$ 810,405 1,660,527
Fixed income Convertible promissory note		2,486,967	25,000	2,486,967 25,000
	\$ 1,660,527	\$ 2,486,967	\$ 25,000	\$ 4,982,899

### 7. Grants payable

Grants payable consist of research grants payable and a commitment to support the establishment of a Dutch center of expertise for Barth syndrome in the Netherlands.

Research grants payable as of December 31, 2024 and 2023 consists of amounts awarded but not paid, of \$146,910 and \$84,650, respectively. All are due to be paid within the next 12 months.

During September 2024, the Organization made a commitment of \$110,000 for funding of the Dutch center of expertise for Barth syndrome.

The Organization is committed to research grants awarded subsequent to year-end, up to the amount of \$260,000, of which \$125,000 is committed to be funded by affiliates (see Note 12).

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 8. Net assets

Net assets were as follows for the years ended December 31, 2024 and 2023:

	Without donor restrictions	2024 With donor restrictions	Total	Without donor restrictions	2023 With donor restrictions	Total
Undesignated	\$ 1,121,367	\$	\$ 1,121,367	\$ 1,322,181	\$	\$ 1,322,181
Specific purpose: Restricted for Arrhythmia Science and Medicine Family Services Fund Research grants Chan Zuckerberg Initiative -		88,923 161,718 12,457 6,250	88,923 161,718 12,457 6,250		10,150 157,192 30,684	10,150 157,192 30,684
Rare as One Cycle 3 Therapy Fund		90,549 3,739,022	90,549 3,739,022	-	3,765,147	3,765,147
Total net assets	\$ 1,121,367	\$ 4,098,919	\$ 5,220,286	\$ 1,322,181	\$3,963,173	\$ 5,285,354

Releases from net assets with donor restrictions are as follows at December 31:

2024		2023	
\$	113,819	\$	173,266
	83,750		76,788
	37,836		
	21,227		33,244
	12,279		•
	9,451		
\$	278,362	\$	283,298
		\$ 113,819 83,750 37,836 21,227 12,279 9,451	\$ 113,819 \$ 83,750 37,836 21,227 12,279 9,451

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 9. Contributed nonfinancial assets

Donated services have been recognized as support and revenue; and, related expense on the accompanying financial statements. Donated services require professional skills, and would typically be purchased if not provided by donation, and are valued based on current rates for similar services. These are reported as part of in-kind professional services in the statement of functional expenses.

	2024				
	Program services	Management and general	Fundraising	Total	
Donated services – BSF Regional meetings	\$ 44,937	\$	\$	\$ 44,937	
	\$ 44,937	\$	\$	\$ 44,937	
	2023				
	Program services	Management and general	Fundraising	Total	
Donated services - advocacy					
and awareness	\$ 95,875	\$	\$	\$ 95,875	
	\$ 95,875	\$	\$	\$ 95,875	

### 10. Conditional contributions

During October 2024, the Organization and the Silicon Valley Community Foundation entered into a contribution agreement for the Chan Zuckerberg Initiative - Rare as One Cycle 3 RFA project with a potential maximum contribution of \$800,000. The Organization recognized \$100,000 of this contribution during the year ended December 31, 2024 with payments to be received over four years. The remaining \$700,000 of the contribution is conditional to the performance of certain obligations that the Organization has to meet.

### 11. Major sources of support

Two donors accounted for approximately 23% and 27% of total support and revenues for the years ended December 31, 2024 and 2023, respectively.

### NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023

### 12. Research grant expenses

The Organization, as part of its mission to fund and facilitate research addressing the causes, diagnosis, treatment, and cure of Barth syndrome, commits to certain research grants which it records as research grants payable on the balance sheet, upon approval of the award.

The related research grant award is reported on the statement of functional expenses to reflect the full grant expenditure amount of \$322,746 and \$333,038 for the years ended December 31, 2024 and 2023, respectively. From time to time, the Organization receives assistance from affiliated entities to cover portions of the research grant awards. These amounts have been recorded on the statement of activities as affiliate donation for research grant. The affiliates' funding for the research grant were \$190,000 and \$76,788 for the years ended December 31, 2024 and 2023, respectively.

### 13. Retirement plans

The Organization has a 401(k) Plan covering all eligible employees upon hire. The Organization contributions are made on a per-pay period basis based on the amount of the employee's pre-tax and/or Roth contributions. The employer match is 100% of employee deferrals up to the first 3% of compensation for the period and 50% of the next 2% of compensation for the year, and is immediately vested. Contributions during the years ended December 31, 2024 and 2023 amounted to \$23,308 and \$22,411, respectively.

### 14. Subsequent events

The Organization has evaluated subsequent events through April 15, 2025 which is the date the financial statements were available to be issued. The Organization is not aware of any material subsequent events.